ZEVRA THERAPEUTICS INC. - COMMON STOCK

Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

10 10 2024 07:30:00 提供 Nasdaq GlobeNewswire

NUCDF and Zevra Therapeutics Launch Check Ammonia Campaign to Highlight Critical Importance of Prompt, Accurate Blood Ammonia Testing for Diagnosing Urea Cycle Disorders

09 10 2024 09:00:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024

24 9 2024 07:30:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics’ MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C

20 9 2024 12:08:07 提供 Nasdaq GlobeNewswire

Zevra Therapeutics Presented New Data for Arimoclomol and OLPRUVA® (Sodium Phenylbutyrate) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium

06 9 2024 08:30:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics to Participate at Upcoming Investor Conferences

29 8 2024 07:30:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights

13 8 2024 16:05:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics Announces Pricing of Underwritten Offering of Common Stock

09 8 2024 00:00:03 提供 Nasdaq GlobeNewswire

Zevra Therapeutics Announces Proposed Public Offering of Common Stock

08 8 2024 16:01:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics to Present at Canaccord Genuity’s 44th Annual Growth Conference

07 8 2024 09:34:47 提供 Nasdaq GlobeNewswire

FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C

02 8 2024 17:50:37 提供 Nasdaq GlobeNewswire

Zevra Therapeutics to Report Second Quarter 2024 Financial Results

30 7 2024 08:38:30 提供 Nasdaq GlobeNewswire

Zevra Announces FDA Advisory Committee Meeting to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C

09 7 2024 09:00:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics Expands Executive Leadership Team

25 6 2024 07:30:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders

18 6 2024 07:30:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting

03 6 2024 11:00:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics to Participate at Upcoming Investor Events

09 5 2024 07:30:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates

08 5 2024 07:00:01 提供 Nasdaq GlobeNewswire

Zevra Therapeutics to Report First Quarter 2024 Results on May 8, 2024

01 5 2024 07:30:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics’ President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024

29 4 2024 07:30:00 提供 Nasdaq GlobeNewswire